No-Cell-Collection CAR-T: new shot at blood cancer remission?
NCT ID NCT07485504
First seen Mar 28, 2026 · Last updated May 24, 2026 · Updated 7 times
Summary
This early study tests a new treatment called DIT101 for people with blood cancers that have come back or stopped responding to standard therapy. DIT101 is a type of CAR-T therapy that works inside the body, so patients don't need to have their cells collected and modified in a lab. The study will check if DIT101 is safe and whether it can shrink tumors, with about 15 adults taking part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hematology Hospital of Chinese Academy of Medical Sciences (Hematology Research Center of Chinese Academy of Medical Sciences)
Tianjin, China
Conditions
Explore the condition pages connected to this study.